

Ratnappan et al., REVISED Table S5: Effect of *daf-16* mutation on the longevity conferred by NHR-49 overexpression

**S5A: *daf-16* mutant background**

#	Strain	Trial 1					Trial 2				
		n = Obs/Total <sup>a</sup>	Mean ± SEM	P (vs. N2)	P (vs. P vs. <i>daf-16</i> , <i>daf-16</i> ; <i>Pnhr-49::nhr-49::GFP</i> and <i>nhr-49</i> )	% Lifespan Change	n = Obs/Total <sup>a</sup>	Mean ± SEM	P (vs. N2)	P (vs. <i>daf-16</i> , <i>daf-16</i> ; <i>Pnhr-49::nhr-49::GFP</i> and <i>nhr-49</i> )	% Lifespan Change
1	N2	67/109	18.5 ± 0.3				106/24	18.6 ± 0.3			
2	<i>nhr-49(nr2041)</i>	87/96	12.7 ± 0.1	<0.0001		-31	116/118	11.2 ± 0.1	<0.0001		-40
3	<i>daf-16(mu86)</i>	56/120	15.6 ± 0.2	0.001		-16	62/122	15.6 ± 0.2	0.001		-16
4	<i>Pnhr-49::nhr-49::GFP</i>	40/98	24.9 ± 0.2	<0.0001	<0.0001 (P vs <i>daf-16</i> , <i>daf-16</i> ; <i>Pnhr-49::nhr-49::GFP</i> and <i>nhr-49</i> )	+ 34	37/115	24.1 ± 0.1	<0.0001	<0.0001 (P vs <i>daf-16</i> , <i>daf-16</i> ; <i>Pnhr-49::nhr-49::GFP</i> and <i>nhr-49</i> )	+ 29
5	<i>daf-16(mu86); Pnhr-49::nhr-49::GFP</i>	56/96	17.4 ± 0.3	0.26	0.11 (vs. <i>daf-16</i> )	- 6	82/118	16.3 ± 0.2	0.001	0.03 (vs. <i>daf-16</i> )	-12

**S5B: *daf-16*; *glp-1* mutant background**

1	<i>glp-1</i>	75/91	36.9 ± 0.2				72/80	31.6 ± 0.3			
2	<i>nhr-49; glp-1</i>	76/100	14.2 ± 0.2	<0.0001 (vs. <i>glp-1</i> )			47/64	15.7 ± 0.3	<0.0001 (vs. <i>glp-1</i> )		
3	<i>daf-16; glp-1</i>	75/90	20.4 ± 0.3	<0.0001 (vs. <i>glp-1</i> )			70/80	17.6 ± 0.3	<0.0001 (vs. <i>glp-1</i> )		
4	<i>daf-16; glp-1; NHR-49::GFP</i>	74/89	22.8 ± 0.3	<0.0001 (vs. <i>glp-1</i> )	0.001 (P vs. <i>daf-16; glp-1</i> ); 0.16 (vs. non-transgenic sibling)		74/91	20.1 ± 0.2	<0.0001 (vs. <i>glp-1</i> )	0.001 (P vs. <i>daf-16; glp-1</i> ); 0.002 (vs. non-transgenic sibling)	
5	<i>daf-16; glp-1; NHR-49::GFP</i> non-transgenic siblings	80/90	20.2 ± 0.2	<0.0001 (vs. <i>glp-1</i> )	0.17 (vs. <i>daf-16; glp-1</i> )		63/80	22.3 ± 0.5	<0.0001 (vs. <i>glp-1</i> )	<0.0001 (vs. <i>daf-16; glp-1</i> )	